Skip to main content

Table 1 Extension Phase Baseline Patient Characteristics

From: Atomoxetine for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children with ADHD and dyslexia

Characteristic ADHD (N = 20) ADHD+D (N = 36)
Gender, male, n (%) 15 (75.0) 24 (66.7)
Age, years, mean (SD) 12.7 (1.5) 12.2 (2.0)
Ethnic origin, n (%)   
   Caucasian 14 (70.0) 24 (66.7)
   African-American 1 (5.0) 5 (13.9)
   Hispanic 4 (20.0) 4 (11.1)
   Other 1 (5.0) 3 (8.3)
ADHD subtype, n (%)   
   Hyperactive/Impulsive 0 (0) 2 (5.6)
   Inattentive 9 (45.0) 15 (41.7)
   Combined 11 (55.0) 19 (52.8)
Educational services - placement, n (%)a   
   Regular education 7 (35.0) 3 (8.3)
   Regular education/Resource room 7 (35.0) 11 (30.6)
   Regular education/Special education 4 (20.0) 14 (38.9)
   Self-contained special education/Integration 1 (5.0) 5 (13.9)
   Self-contained special education/No integration 0 (0) 3 (8.3)
   Private school - disabilities 1 (5.0) 0 (0)
K-BIT, mean (SD) IQ composite 97.2 (11.9) 102.1 (11.0)
  1. a p-value ≤ .05 for between-group difference.
  2. Abbreviations: ADHD = attention-deficit/hyperactivity disorder group; ADHD+D = ADHD and dyslexia group; K-BIT = Kaufman Brief Intelligence Test; n = sample size; SD = standard deviation.